CryoPort Inc (NASDAQ:CYRX)‘s stock had its “outperform” rating restated by investment analysts at Cowen and Company in a note issued to investors on Tuesday, MarketBeat Ratings reports. They currently have a $11.00 price target on the stock, up from their previous price target of $7.50. Cowen and Company’s target price would suggest a potential upside of 20.35% from the stock’s current price.
Other equities analysts have also issued research reports about the stock. Needham & Company LLC increased their price objective on shares of CryoPort from $8.50 to $10.00 and gave the company a “buy” rating in a research report on Wednesday, August 30th. Janney Montgomery Scott increased their price objective on shares of CryoPort from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday, August 9th.
Shares of CryoPort (CYRX) traded down 0.44% during trading on Tuesday, reaching $9.14. 232,265 shares of the company were exchanged. The stock’s 50 day moving average is $7.21 and its 200 day moving average is $4.46. CryoPort has a 1-year low of $1.80 and a 1-year high of $9.48. The company’s market capitalization is $225.52 million.
CryoPort (NASDAQ:CYRX) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. CryoPort had a negative net margin of 63.77% and a negative return on equity of 48.00%. The business had revenue of $2.92 million during the quarter, compared to analyst estimates of $2.84 million. Equities analysts anticipate that CryoPort will post ($0.72) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “CryoPort’s (CYRX) Outperform Rating Reaffirmed at Cowen and Company” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/2886627/cryoport-inc-cyrx-pt-raised-to-11-00.html.
Institutional investors have recently added to or reduced their stakes in the company. Northern Trust Corp lifted its holdings in shares of CryoPort by 105.0% in the 2nd quarter. Northern Trust Corp now owns 22,179 shares of the company’s stock worth $109,000 after acquiring an additional 11,358 shares during the last quarter. BerganKDV Wealth Management LLC lifted its holdings in shares of CryoPort by 157.5% in the 2nd quarter. BerganKDV Wealth Management LLC now owns 25,750 shares of the company’s stock worth $127,000 after acquiring an additional 15,750 shares during the last quarter. EAM Investors LLC bought a new stake in shares of CryoPort in the 2nd quarter worth about $552,000. D.A. Davidson & CO. lifted its holdings in shares of CryoPort by 16.6% in the 2nd quarter. D.A. Davidson & CO. now owns 137,000 shares of the company’s stock worth $674,000 after acquiring an additional 19,500 shares during the last quarter. Finally, Taylor Wealth Management Partners bought a new stake in shares of CryoPort in the 2nd quarter worth about $1,851,000. Hedge funds and other institutional investors own 12.05% of the company’s stock.
Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.
Receive News & Ratings for CryoPort Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort Inc and related companies with MarketBeat.com's FREE daily email newsletter.